The P-Ib dose escalation part of the study assessed the safety, tolerability, PK profile, provisional RP2D & preliminary antitumor activity of ORIC-114 for treating solid tumors associated with EGFR & HER2 exon 20 mutations as well as HER2 amplifications
ORIC concluded the dose escalation part of the study and selected 80mg & 120mg QD as provisional RP2D to be further evaluated for final RP2D in the P-Ib dose expansion part assessing ORIC-114’s safety & efficacy in mutated NSCLC patients incl. EGFR exon 20, HER2 exon 20 & EGFR atypical mutations
Furthermore, the company has commenced an extension arm to investigate ORIC-114 for 1L, treatment-naïve EGFR exon 20 NSCLC treatment. Updated P-Ib data is anticipated in H1’25
Ref: ORIC Pharmaceuticals | Image: ORIC Pharmaceuticals
Related News:- Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) for KRASG12C-Mutated NSCLC in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
